Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for ...

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...

Kenvue's improvements in marketing and management could drive future growth. Read why there is potential for a turnaround for ...

Arizona Attorney General Kris Mayes on Thursday sued pharmaceutical manufacturer GlaxoSmithKline for engaging in deceptive and unfair practices ...

The lawsuit filed Thursday in Maricopa County Superior Court by Arizona Attorney General Kris Mayes, citing the Arizona Consumer ... says, "GSK put corporate greed ahead of the health and safety ...

The lawsuit filed in Maricopa County Superior Court contends GlaxoSmithKline's actions violate the Arizona Consumer Fraud Act ...

GlaxoSmithKline would consider buying Pfizer’s consumer health business – but only if the price is right, according to the company's chief executive. Emma Walmsley has also been busy shaking ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

GSK's HIV business, run through joint venture company ViiV Healthcare, also had a good quarter with sales up 14% to £1.4 billion, led by gains for two-drug oral regimens Dovato (dolutegravir ...